Clinical Trial Update: 5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating azacitidine in combination with lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia has completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• Revlimid (lenalidomide)
• VIDAZA (AZACITIDINE)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-02-10